How does the patient benefit from clinical PET?

Theranostics

Volumn 2, Issue 5, 2012, Pages 427-436

  Sörensen, Jens ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Patient; PET; PET CT

Indexed keywords

CARBON 11; FLUORINE 18; FLUORODEOXYGLUCOSE; GALLIUM 68; IODINE 124; IODINE 131;

CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DOSIMETRY; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; ISOTOPE LABELING; ISOTOPE TRACING; LUNG CANCER; LYMPHOMA; MEDICARE; MOLECULAR IMAGING; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; REVIEW; SOLID TUMOR; TREATMENT PLANNING; TREATMENT RESPONSE; UNITED STATES;

EID: 84864533600     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.3794     Document Type: Review

References (35)

1. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. Journal of nuclear medicine. 2001; 42: 1S-93S.
2. Lindsay MJ, Siegel BA, Tunis SR, Hillner BE, Shields AF, Carey BP, et al. The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development. AJR American journal of roentgenology. 2007; 188: 1109-13. doi:10.2214/AJR.06.1175.
3. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. Journal of nuclear medicine. 2000; 41: 1369-79.
4. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. The New England Journal of Medicine. 2003; 348: 2500-7. doi:10.1056/NEJMoa022136.
5. Palmetto GBA. Railroad Medicare - FDG PET for Solid Tumors and Myeloma. Medicare; 2009.
6. Tomasi G, Turkheimer F, Aboagye E. Importance of Quantification for the Analysis of PET Data in Oncology: Review of Current Methods and Trends for the Future. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging. 2011;. doi:10.1007/s11307-011-0514-2.
7. Weber WA. Assessing tumor response to therapy. Journal of nuclear medicine. 2009; 50 Suppl 1: 1S-10S. doi:10.2967/jnumed.108.057174.
8. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. Journal of nuclear medicine. 2009; 50 Suppl 1: 21S-30S. doi:10.2967/jnumed.108.057190.
9. de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. Journal of nuclear medicine. 2007; 48: 1592-8. doi:10.2967/jnumed.107.043414.
10. Vriens D, de Geus-Oei LF, van Laarhoven HW, Timmer-Bonte JN, Krabbe PF, Visser EP, et al. Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. Nuclear Medicine Communications. 2009; 30: 550-7. doi:10.1097/MNM.0b013e32832bdc80.
11. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. Journal of nuclear medicine. 2009; 50 (Suppl 1): 122S-50S. doi:10.2967/jnumed.108.057307.
12. Xu GZ, Zhu XD, Li MY. Accuracy of whole-body PET and PET-CT in initial M staging of head and neck cancer: a meta-analysis. Head & Neck. 2011; 33: 87-94. doi:10.1002/hed.21400.
13. Ahn PH, Garg MK. Positron emission tomography/computed tomography for target delineation in head and neck cancers. Seminars in Nuclear Medicine. 2008; 38: 141-8. doi:10.1053/j.semnuclmed.2007.11.002.
14. Yu HM, Liu YF, Hou M, Liu J, Li XN, Yu JM. Evaluation of gross tumor size using CT, 18F-FDG PET, integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer. European Journal of Radiology. 2009; 72: 104-13. doi:10.1016/j.ejrad.2008.06.015.
15. [Internet] NCBI. Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf. http://www.ncbi.nlm.nih.gov/books/NBK5330/.
16. Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sorensen J, Bergstrom M, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nuclear Medicine and Biology. 2010; 37: 265-75. doi:10.1016/j.nucmedbio.2009.11.008.
17. Velikyan I. Positron emitting [68Ga]Ga-based imaging agents: chemistry and diversity. Med Chem. 2011; 7: 345-79.
18. Lubberink M, Herzog H. Quantitative imaging of 124I and 86Y with PET. European Journal of Nuclear Medicine and Molecular Imaging. 2011; 38 Suppl 1: S10-8. doi:10.1007/s00259-011-1768-2.
19. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clinical pharmacology and therapeutics. 2010; 87: 586-92. doi:10.1038/clpt.2010.12.
20. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. The Journal of clinical endocrinology and metabolism. 2005; 90: 3392-400. doi:10.1210/jc.2004-1938.
21. Sherif HM, Nekolla SG, Saraste A, Reder S, Yu M, Robinson S, et al. Simplified quantification of myocardial flow reserve with flurpiridaz F 18: validation with microspheres in a pig model. Journal of nuclear medicine. 2011; 52: 617-24. doi:10.2967/jnumed.110.083196.
22. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET Imaging of Integrin alphaVbeta3 Expression. Theranostics. 2011; 1: 48-57.
23. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55: 306-19. doi:10.1002/ana.20009.
24. Laforce R, Jr., Rabinovici GD. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther. 2011; 3: 31. doi:10.1186/alzrt93.
25. Langstrom B, Grahnen A, Honore PH, Borlak J, Bergstrom M, Nielsen B, et al. The risk of exaggerated risk aversion-a life and death struggle for molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2009; 36: 1693-4. doi:10.1007/s00259-009-1190-1.
26. Lundqvist H, Antoni G, Langstrom B. Genotoxic hazard of radiopharmaceuticals in humans: chemical and radiation aspects coupled to microdosing. Eur J Clin Pharmacol. 2007; 63: 641-5. doi:10.1007/s00228-007-0304-6.
27. [Internet] FDA. Critical Path Initiative. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm.
28. Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 2011; 10: 667-70. doi:10.1016/S1474-4422(11)70123-5.
29. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. Journal of nuclear medicine. 2008; 49: 68-78. doi:10.2967/jnumed.106.037200.
30. Ribom D, Schoenmaekers M, Engler H, Smits A. Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas. Journal of Neuro-Oncology. 2005; 71: 325-32. doi:10.1007/s11060-004-2031-5.
31. Hessman O, Stalberg P, Sundin A, Garske U, Rudberg C, Eriksson LG, et al. High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J Surg. 2008; 32: 774-81. doi:10.1007/s00268-008-9537-5.
32. Hennings J, Lindhe O, Bergstrom M, Langstrom B, Sundin A, Hellman P. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. The Journal of clinical endocrinology and metabolism. 2006; 91: 1410-4. doi:10.1210/jc.2005-2273.
33. Trampal C, Engler H, Juhlin C, Bergstrom M, Langstrom B. Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology. 2004; 230: 423-8. doi:10.1148/radiol.2302021678.
34. Sörensen J, Valind S, Andersson LG. Simultaneous quantification of myocardial perfusion, oxidative metabolism, cardiac efficiency and pump function at rest and during supine bicycle exercise using 1-11C-acetate PET - a pilot study. Clinical Physiology and Functional Imaging. 2010; 30: 279-84.
35. Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology. 2006; 67: 996-1000. doi:10.1016/j.urology.2005.11.044.